RG 7600

Drug Profile

RG 7600

Alternative Names: DMOT 4039A; RG7600

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Genentech
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Megakaryocyte potentiating factor inhibitors; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Ovarian cancer; Pancreatic cancer

Most Recent Events

  • 16 Oct 2014 Discontinued - Phase-I for Ovarian cancer (Second-line therapy or greater) in Netherlands (IV)
  • 16 Oct 2014 Discontinued - Phase-I for Ovarian cancer (Second-line therapy or greater) in USA (IV)
  • 16 Oct 2014 Discontinued - Phase-I for Pancreatic cancer (Inoperable/Unresectable) in Netherlands (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top